Evaluating Blood Tests and Diagnostic Accuracy in Alzheimer's Disease Management

May 5, 2026, 11:00
GlobalHealth

Introduction

Recent improvements in blood-based biomarker tests aim to make the early detection of Alzheimer's disease easier, although general delays in diagnosis continue to hinder the enrollment of patients in clinical trials.

Main Body

Measuring the p-tau217 protein has shown the ability to predict when Alzheimer's symptoms will start, usually with an error of only three to four years. Research shows that higher protein levels are linked to how soon symptoms will appear; for example, high levels at age 60 usually mean symptoms will start in twenty years, whereas high levels at age 80 suggest a shorter wait of about eleven years. However, the Alzheimer's Association emphasized that these tests are not standalone diagnostic tools. They asserted that these tests should only be used in specialized clinics for patients who already show cognitive impairment, because there is not enough data for people without symptoms and there is a risk of wrong results due to other health issues, such as kidney disease. At the same time, there is a clear gap between the number of new experimental drugs and the number of available patients. While the number of potential drugs has increased by 40% over the last ten years—moving from removing amyloid to focusing on tau and inflammation—recruitment in the UK remains low. Alzheimer's Research UK stated that many patients do not have a formal or specific enough diagnosis, which consequently prevents them from joining phase 3 trials. This lack of diagnostic progress may weaken the current research momentum, especially regarding the use of medicines like lecanemab and donanemab in the early stages of the disease.

Conclusion

Although blood-based biomarkers provide a promising way to intervene earlier, their use in clinics depends on further validation and the closing of existing diagnostic gaps.

Learning

The 'Nuance Gap': Moving from Simple to Complex Cause & Effect

An A2 student usually says: "People have kidney disease, so the test is wrong."

A B2 speaker uses Connectors of Consequence and Limitation to show a sophisticated relationship between ideas.

⚡ The Linguistic Shift

Look at these two phrases from the text:

  1. *"...which consequently prevents them from joining..."
  2. *"...although general delays in diagnosis continue to hinder..."

The Logic:

  • Consequently: This is the 'Professional' version of so. It doesn't just show a result; it shows a logical chain of events. Use this when you want to sound more academic or precise.
  • Although: This is the 'Bridge' word. Instead of using but in the middle of a sentence, putting although at the start creates a complex sentence structure that B2 examiners love. It acknowledges a fact while introducing a conflicting problem.

🛠️ Application: Rebuilding the Sentence

Level A2 (Basic): Blood tests are good. But they are not used everywhere because we need more data.

Level B2 (Bridged): Although blood tests are promising, they are not yet used in all clinics; consequently, many patients still face delays in diagnosis.

💡 Quick Tip for the Transition

To move toward B2, stop using but, so, and because at the start of every sentence. Try replacing them with:

  • Because →\rightarrow Due to the fact that...
  • So →\rightarrow Consequently... / Therefore...
  • But →\rightarrow However... / Although...

Vocabulary Learning

biomarker (n.)
A measurable indicator of a biological condition.
Example:The blood-based biomarker tests can detect early signs of Alzheimer’s disease.
diagnostic (adj.)
Relating to identifying a disease.
Example:These tests are not standalone diagnostic tools.
enrollment (n.)
The process of registering participants in a study.
Example:General delays in diagnosis continue to hinder the enrollment of patients in clinical trials.
clinical (adj.)
Relating to the observation and treatment of patients.
Example:The use of these tests in clinics depends on further validation.
predict (v.)
To forecast or estimate something that will happen.
Example:Measuring the p-tau217 protein has shown the ability to predict when symptoms will start.
specialized (adj.)
Tailored for a specific purpose or area.
Example:These tests should only be used in specialized clinics for patients who already show cognitive impairment.
cognitive (adj.)
Related to mental processes of perception and understanding.
Example:The patients already show cognitive impairment.
impairment (n.)
A loss or reduction in ability or function.
Example:Cognitive impairment is a common early sign of Alzheimer’s disease.
inflammation (n.)
The body's response to injury or infection, often causing swelling.
Example:The focus on tau and inflammation represents a shift in treatment strategies.
validation (n.)
Confirmation that something is accurate or reliable.
Example:Further validation is needed before these tests can be widely used.
intervene (v.)
To act in order to change a situation or outcome.
Example:Blood-based biomarkers provide a promising way to intervene earlier.
gap (n.)
A missing or incomplete part between two points.
Example:There is a clear gap between the number of new experimental drugs and the number of available patients.
momentum (n.)
The force that keeps something moving forward.
Example:The lack of diagnostic progress may weaken the current research momentum.
phase (n.)
A distinct period or stage in a process.
Example:Many patients do not have a formal diagnosis, preventing them from joining phase 3 trials.
association (n.)
A group of people with a common purpose or interest.
Example:The Alzheimer’s Association emphasized that these tests are not standalone diagnostic tools.